Serina Therapeutics, Inc. (NYSEAMERICAN:SER) Sees Large Decrease in Short Interest

Serina Therapeutics, Inc. (NYSEAMERICAN:SER) was the target of a large decline in short interest in August. As of August 31st, there was short interest totaling 70,094 shares, a decline of 51.8% from the August 15th total of 145,548 shares. Currently, 0.3% of the shares of the stock are sold short. Based on an average daily trading volume, of 53,172 shares, the days-to-cover ratio is currently 1.3 days.

Serina Therapeutics Trading Down 4.1%

NYSEAMERICAN:SER traded down $0.10 on Tuesday, reaching $2.35. The stock had a trading volume of 31,675 shares, compared to its average volume of 62,408. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.65 and a quick ratio of 6.65. Serina Therapeutics has a 1-year low of $1.22 and a 1-year high of $5.83. The stock has a fifty day moving average price of $2.39 and a 200-day moving average price of $2.07.

Serina Therapeutics (NYSEAMERICAN:SER) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.55) earnings per share for the quarter.

Wall Street Analysts Forecast Growth

Separately, BTIG Research reiterated a “buy” rating and set a $8.00 price objective on shares of Serina Therapeutics in a research note on Thursday, September 10th. One investment analyst has rated the stock with a Buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $8.00.

Serina Therapeutics Company Profile

Serina Therapeutics, Inc, a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson’s disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson’s disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc was founded in 2006 and is based in Huntsville, Alabama.